Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Pericardial metastases

Pericardial metastases are secondary sites of neoplastic disease in the pericardium, the serous structure surrounding the heart. Involvement may be microscopic, nodular or diffusely infiltrative and may be accompanied by effusion, thickening of the pericardial layers, adhesions and, in advanced cases, impaired cardiac filling. The most common clinical manifestation is pericardial effusion, but the amount of fluid alone indicates neither the extent of the neoplasm nor the severity of haemodynamic impairment.

It is essential to distinguish an effusion with documented malignant cells or tissue infiltration from the broader group of effusions occurring in people with cancer. The latter may result from lymphatic obstruction without demonstrable infiltration, treatment effects, infection, renal failure, heart failure or other conditions. Therefore, use of the term malignant effusion requires assessment of the diagnostic evidence on which it is based. This distinction guides treatment and staging and prevents every fluid collection from being interpreted as cancer progression.

Pericardial involvement may coexist with myocardial or intracavitary cardiac metastases, but poses specific challenges: recognising tamponade, obtaining diagnostic material, preventing fluid reaccumulation and distinguishing compression by fluid from constriction caused by infiltrating tissue. Treatment must coordinate these local problems with control of the primary neoplasm.

Aetiology and routes of spread

Lung and breast cancers are among the most common causes of secondary pericardial involvement; lymphomas, leukaemias, melanoma and tumours from other sites complete a broad aetiological spectrum. The observed distribution depends on the prevalence of primary tumours, the population receiving care and the way malignancy is established. Autopsy series include clinically silent infiltration that does not correspond solely to effusions drained in clinical practice. It is therefore inappropriate to transfer an autopsy percentage directly to the probability that an individual effusion is neoplastic.

Tumour cells can reach the pericardium through haematogenous or lymphatic dissemination. Mediastinal lymph-node disease may impair drainage and promote spread along the pericardial layers. A thoracic tumour may also invade the pericardium by direct extension: this type of secondary involvement is often discussed alongside metastases, although it has a different anatomical meaning and, depending on the primary tumour, a different staging classification. Establishing continuity with the pleura, lung or mediastinum is therefore part of the diagnostic work-up.

Obstruction of lymphatic pathways can cause fluid accumulation even without identifiable neoplastic cells in the pericardium. In this context, the term paramalignant effusion is sometimes used to describe an indirect relationship with cancer rather than a specific histological diagnosis. In the same patient, infiltration, impaired drainage and systemic factors such as hypoalbuminaemia or venous congestion may coexist. A multifactorial explanation is often more accurate than attributing the collection exclusively to a single mechanism.

A new effusion during treatment also calls for consideration of iatrogenic pericardial disease. Thoracic radiotherapy, certain antineoplastic drugs and immunomodulatory treatments may cause pericardial inflammation or damage with varying times of onset. Immunotherapy may be associated with pericarditis and, in some cases, other immune-mediated cardiac manifestations. The exposure history guides investigations but does not replace the search for progression or infection. Decisions to interrupt or modify treatment require clarification, as far as possible, of the underlying mechanism.

Pathogenesis of effusion, tamponade and constriction

Neoplastic infiltration alters vascular permeability, serosal integrity and lymphatic resorption. The fluid may be serous, serosanguineous or frankly bloody; a haemorrhagic appearance raises suspicion in the appropriate context, but may also occur following trauma, procedures, infections or other diseases. Nodules, fibrin and adhesions may compartmentalise the collection, producing loculated effusions. Conversely, extensive solid pericardial disease may be associated with little fluid.

Cardiac tamponade develops when pressure within the pericardial sac impairs chamber filling and reduces cardiac output. The relationship between volume and pressure is nonlinear: slow accumulation allows some adaptation, whereas rapid accumulation may cause severe compromise with smaller fluid volumes. Intravascular volume, intracardiac pressures and the distribution of fluid also matter. Thus, the echocardiographic diameter of an effusion and blood pressure, considered in isolation, are insufficient to exclude early tamponade.

As pericardial pressure increases, venous return and filling become progressively restricted. Tachycardia and vasoconstriction can temporarily maintain systemic pressure while congestion and reduced organ perfusion develop. Increased ventricular interdependence contributes to respiratory variations in flow and to pulsus paradoxus. Severity depends on the combination of physiology, symptoms and clinical course: a patient who is still normotensive may have substantial impairment, especially when compensation is sustained by a pronounced adrenergic response.

In loculated collections, compression may be regional, with less typical findings than in a circumferential effusion. In pulmonary hypertension or with elevated right-sided pressures, the usual right-chamber collapse may be absent; in hypovolaemic patients, tamponade may occur without obvious jugular venous distension. Mechanical ventilation, arrhythmias and other cardiac diseases modify Doppler signs. Therefore, tamponade physiology must be interpreted in the patient's actual clinical conditions.

An infiltrated, fibrotic or adherent pericardium may persistently restrict diastolic expansion and cause constriction. In effusive-constrictive disease, the effusion and restriction of the visceral pericardium jointly impair filling: after drainage, some congestion and constrictive physiology persist. This picture must be distinguished from residual fluid, ventricular dysfunction, volume overload or severe pulmonary disease. Removing the collection relieves compression caused by the fluid but may leave unchanged the solid component responsible for constriction.

Clinical manifestations and bedside assessment

A small or slowly progressive effusion may be an incidental finding. When symptoms occur, dyspnoea, orthopnoea, fatigue, reduced exercise tolerance and a sensation of chest heaviness are common. Pleuritic or positional pain suggests an inflammatory component, which may or may not accompany neoplastic infiltration. Cough, fever, weight loss and chest pain may also reflect the primary cancer, pleural disease or concomitant infection. Assessment must relate symptoms to documented physiology rather than using the mere presence of fluid as a universal explanation.

With haemodynamic deterioration, tachycardia, narrowed pulse pressure, oliguria, presyncope and signs of hypoperfusion may develop. Hypotension, jugular venous distension and muffled heart sounds form the classic description of tamponade, but the complete triad is inconsistent. Pulsus paradoxus, when present and properly assessed, increases suspicion; its absence does not exclude the condition. In constrictive forms, oedema, ascites, hepatomegaly and persistent venous congestion often predominate, sometimes with less obvious dyspnoea than the severity of functional limitation might suggest.

History-taking should clarify the course of the effusion, previous drainage procedures, cytological findings, intrapericardial or surgical treatments and the speed of recurrence. The cancer history, thoracic irradiation, recent medications, anticoagulant use, thrombocytopenia and infectious risk should be reviewed. Epidemiological context for tuberculosis and immunosuppression can also change interpretation. Comparing symptoms and imaging with the course of other tumour sites helps identify concordant progression or a pericardial process of a different nature.

Echocardiography and multimodality imaging

Echocardiography is the initial reference examination for demonstrating fluid and assessing its consequences. It describes distribution, size, possible septations or masses, biventricular function and relationships to the chambers. Measuring the echo-free space helps monitor progression but is not an accurate measurement of total volume. When tamponade is suspected, right atrial and ventricular collapse during the appropriate phases of the cardiac cycle, respiratory flow variations, the inferior vena cava and their consistency with the clinical state are assessed. Any isolated finding requires interpretation, particularly with hypovolaemia, pulmonary hypertension or assisted ventilation.

When constriction is suspected, the examination assesses respiratory septal motion, ventricular interdependence, and the behaviour of flows and myocardial velocities. After drainage, persistent abnormalities may indicate effusive-constrictive physiology but must be distinguished from other causes of elevated filling pressures. Invasive haemodynamic assessment is reserved for cases in which non-invasive tests leave uncertainty relevant to management. Pericardial thickening alone does not demonstrate haemodynamic constriction, just as minimal thickening does not completely exclude it.

Contrast-enhanced chest CT defines nodularity, thickening, fluid distribution and relationships with pleura, lung, lymph nodes and mediastinum. It helps distinguish contiguous invasion from more widespread involvement, identify posterior or loculated collections and plan access when anatomy is complex. Oncological CT may suggest the problem before symptoms appear but does not replace immediate echocardiographic assessment of haemodynamic consequences. In an unstable patient, completing radiological staging must not delay treatment of cardiac compression.

Cardiac magnetic resonance imaging can clarify pericardial extent, the solid component, relationships with epicardium and myocardium, and functional signs of constriction. Signal characteristics and enhancement help characterise tissue, but inflammation and neoplasia may share some features. PET/CT, in appropriate tumours and clinical questions, helps assess metabolic activity and disease extent and may reveal a more useful biopsy site. Pericardial FDG uptake also remains nonspecific for distinguishing malignancy from inflammation and infection.

ECG, chest radiography and blood tests complete the assessment without independently confirming a neoplastic origin. Low voltages or electrical alternans may accompany a large effusion, whereas a minimally abnormal ECG does not exclude a substantial collection. Blood count, coagulation tests, renal function, electrolytes and inflammatory markers inform diagnosis and procedural safety. Troponin is useful when concomitant myocardial injury is suspected, including treatment-related myopericarditis; an elevation does not automatically establish tumour infiltration.

Fluid analysis and pathological confirmation

When an effusion is drained, specimen collection should be organised to obtain adequate cytology, with cell-block preparation whenever possible. Well-preserved cells enable immunohistochemistry and, where appropriate, molecular testing. The pathologist should be informed about prior tumour, treatments and alternative diagnoses under consideration. If lymphoma is suspected, allocation of part of the sample to flow cytometry and other relevant studies should be agreed before the procedure.

The presence of malignant cells in the fluid documents neoplastic involvement of the pericardial cavity. Determining the site of origin requires morphology and suitable panels because reactive mesothelial cells can exhibit atypia and poorly differentiated tumours may be difficult to classify. Comparison with the primary tumour is especially important when the diagnosis changes treatment. Pericardial mesothelioma, a rare primary tumour of the serosa, requires specific distinction from metastases and reactive mesothelial proliferations; atypical mesothelial cells alone do not establish that diagnosis.

Negative cytology does not rule out malignancy. The tumour may be focal, may not shed cells into the fluid, may be covered by fibrin or may be inadequately represented in the sample. In a multicentre analysis of paired specimens, cytological sensitivity was higher than that of pericardial biopsy, at 84.8% and 65.7%, respectively, in the population studied. This finding shows the value of cytology but is not a universal performance estimate and does not make biopsy unnecessary in appropriate cases. Cytology and histology examine different compartments and may be complementary.

Pericardial biopsy is useful when suspicion remains high, the fluid is nondiagnostic and the result could change treatment. Targeted sampling of a nodule or abnormal area increases the likelihood of obtaining representative tissue compared with random sampling of apparently unaffected serosa. The procedure may be combined with a surgical window or other techniques available in experienced centres. Before choosing invasive pericardial access, the availability of an easier extracardiac biopsy site should also be assessed, ensuring that it addresses the clinical question.

Biochemical analyses and cell counts aid assessment, but protein-rich or bloody fluid does not identify the cause. Tumour markers in the effusion do not replace cytological or histological demonstration, and their interpretation is limited by overlap and methodological variability. Microbiological tests should be selected according to the clinical presentation, immunosuppression and epidemiology. Infection, including tuberculosis in relevant settings, must remain in the differential diagnosis even when a neoplasm is already known.

Disease definition and treatment planning

Following confirmation, oncological staging is updated according to the primary cancer. Demonstration of pericardial dissemination can substantially change staging and treatment goals, whereas contiguous invasion follows the staging rules for the primary tumour. In cases without a known neoplasm, histology guides the search for the primary site and staging investigations. Positive cytology does not necessarily complete the characterisation: predictive biomarkers or further tissue may be needed to select treatment.

Local management requires information about the rate of fluid reaccumulation, free or loculated distribution, the presence of solid infiltration, tamponade risk and the possibility of a systemic response. Respiratory reserve, performance status, thrombocytopenia, coagulation status and previous thoracic procedures must also be considered. The aim may be to establish the diagnosis, treat an emergency, prevent repeated admissions or enable anticancer treatment to begin. These aims may overlap but should be made explicit to select a proportionate procedure.

Tamponade and indications for drainage

Tamponade causing clinical compromise requires urgent drainage. Image-guided pericardiocentesis is often the most rapidly available treatment, with the approach chosen according to fluid distribution and anatomical relationships. Surgical access may be necessary when the fluid is difficult to reach, organised or loculated, when bleeding must be controlled, or when a surgical diagnostic or therapeutic procedure is also needed. An experienced team capable of managing complications should perform the procedure.

While awaiting the procedure, haemodynamic management must avoid further reduction of preload. Diuretics do not relieve pericardial compression and may worsen low cardiac output in tamponade; cautious volume support may be useful as a temporary measure in selected patients but does not replace drainage. Deep sedation and positive-pressure ventilation may precipitate instability and require particularly careful planning. Completion of staging or waiting for cytology must not delay decompression in an unstable patient.

The presence of thrombocytopenia, coagulation abnormalities or anticoagulation increases procedural complexity. Where the patient's condition allows, correctable abnormalities should be addressed and medication management coordinated; in life-threatening tamponade, the risk of delay must be weighed against bleeding risk. A laboratory threshold alone cannot replace assessment of urgency, accessibility and team expertise. The aim is effective decompression at the lowest possible risk in the actual clinical circumstances.

In stable patients, drainage is mainly indicated when the effusion causes symptoms, shows signs of compromise, enlarges rapidly, or when sampling could change management. A large or progressive collection requires active assessment even without hypotension. For a small or moderate asymptomatic effusion without haemodynamic consequences, surveillance with treatment of the underlying cause may be appropriate. The choice considers the clinical course, rapid access to care and the foreseeable benefit of the procedure, avoiding both passive waiting and interventions without a defined clinical objective.

After initial decompression, the pericardial catheter may be left in place for prolonged drainage, monitoring the volume and appearance of the fluid, catheter patency and the insertion site. This strategy reduces the risk of reaccumulation compared with one-off aspiration alone. Removal is decided based on a sustained decrease in drainage, repeat echocardiography and the clinical situation, according to the centre's protocol. Abrupt cessation of flow, when accompanied by symptoms or residual fluid, may indicate catheter obstruction rather than resolution of the problem.

Decompression must be controlled, with monitoring during and after the procedure. Rare pericardial decompression syndrome consists of haemodynamic deterioration, pulmonary oedema or ventricular dysfunction after apparently effective drainage, sometimes following initial improvement. Proposed mechanisms include abrupt changes in ventricular loading and adrenergic responses; evidence on prevention is limited. Once the immediate compromise has been relieved, gradual continuation of drainage and monitoring are prudent measures. Diagnosis requires exclusion of perforation, bleeding, ischaemia and other acute causes; treatment is supportive, including intensive care when required.

Recurrence and local-control strategies

Recurrent effusion depends on persistent infiltration, impaired drainage and the oncological response. Reaccumulation after aspiration does not necessarily mean that the initial procedure was ineffective: fluid production may simply be ongoing. For recurrent effusions, prolonged catheter drainage, a pericardial window, percutaneous pericardiotomy and, in selected settings, intrapericardial therapies are considered. The choice must integrate the expected duration of benefit, likelihood of systemic response, previous procedures and burden of care.

A pericardial window creates an opening through which fluid can drain and may be performed using different approaches selected according to anatomy and patient condition. It also allows pericardial sampling and may provide more durable control when recurrences are frequent or the fluid is organised. However, anaesthesia, pain, respiratory risk, bleeding and recovery time must be considered. Even after a window, the opening may close, loculated collections may develop or the solid component may progress.

Balloon pericardiotomy is a percutaneous procedure that creates an opening to drain fluid outside the pericardial sac. It may be considered in experienced centres and selected patients when control of recurrence is sought while limiting the burden of surgery. The small randomised PMAP trial found fewer recurrences than with pericardiocentesis and prolonged drainage. However, small sample size, selected population and recruitment difficulties limit generalisability; the study did not demonstrate a survival benefit. These findings inform individual discussion without establishing a mandatory treatment for every malignant effusion.

Instillation of intrapericardial drugs aims to reduce reaccumulation through local antineoplastic action or sclerosis. Agents such as cisplatin, thiotepa and bleomycin have been used in specific settings, with variable results and tolerability. Histological type, tumour sensitivity, treatment availability and centre expertise guide any indication. Pain, inflammation, fever and possible constrictive consequences must be considered; these procedures are not a universal substitute for systemic treatment and require specialist protocols.

Pericardiectomy has a different role from simple drainage or a pericardial window. It may be discussed when persistent constriction predominates and the expected functional benefit justifies a demanding operation. In diffuse neoplastic infiltration, resection may be incomplete or technically risky because of adhesions and involvement of adjacent structures. Assessment must consider tumour controllability, organ reserve and the possibility that symptoms also result from myocardial injury or systemic disease. Radiological thickening alone is not an indication for surgery.

Systemic treatment and supportive care

Control of the primary neoplasm may reduce fluid production and prolong the benefit of local procedures. Chemotherapy, molecularly targeted treatments, endocrine therapy and immunotherapy are selected according to histology, biomarkers, previous lines of treatment and general condition. In sensitive tumours, a response may allow prolonged control of pericardial disease; in refractory cases, local treatment primarily aims to relieve symptoms and limit recurrence. The possibility of a future response to medication does not justify delaying treatment of a current tamponade.

Anti-inflammatory drugs and colchicine have a role when a pericarditic component is present for which they are appropriate. They do not eliminate tumour infiltration or mechanically relieve tamponade. Observations concerning colchicine use after drainage in patients with cancer do not justify indiscriminate use in all malignant effusions. The decision takes account of renal function, interactions, cytopenias, gastrointestinal risk and an actual anti-inflammatory indication. Possible immune-mediated pericarditis requires a specific approach, including investigation for concurrent myocarditis when suggested by the presentation.

Management of congestion in constriction must be cautious: diuretics can improve oedema and ascites, but excessive reduction of circulating volume worsens cardiac output in a heart with restricted filling. Management of pain, dyspnoea and anxiety, nutritional support and mobilisation compatible with clinical condition contribute to quality of life. Antithrombotic treatment should be reassessed around procedures and in the presence of bloody effusion, balancing the original indication against bleeding risk without automatic cessation in the absence of clinical assessment.

Palliative care may be integrated early, including during active cancer treatment. The value of a procedure depends on its ability to improve breathing, reduce emergency visits or allow treatment to continue. In a very frail person with uncontrollable progression, a more invasive intervention may provide little benefit compared with a less burdensome option. Patient preferences and support available at home are part of the decision alongside anatomical and haemodynamic findings.

Follow-up and prognosis

After drainage, follow-up echocardiography assesses residual fluid, cardiac function and resolution of compressive signs. If dyspnoea or congestion persists, effusive-constrictive physiology, myocardial dysfunction, pulmonary embolism, pleural disease and other causes should be considered. In patients managed without a procedure, an early follow-up assessment helps establish effusion dynamics; subsequent intervals depend on stability, size, ongoing treatment and symptoms. No single surveillance schedule is appropriate for every neoplastic presentation.

Monitoring should link the oncological response to the pericardial course. Tumour reduction may precede or follow the decrease in fluid; a persistent effusion may reflect residual lymphatic or inflammatory damage. Conversely, rapid reaccumulation requires assessment for progression, drainage-catheter or window patency and possible coexisting causes. Rapidly worsening dyspnoea, presyncope, hypotension or reduced urine output require earlier assessment without waiting for the scheduled visit.

Prognosis depends primarily on tumour type, extent and treatment sensitivity, as well as cardiovascular reserve and overall condition. Positive cytology often accompanies advanced disease and is associated with adverse outcomes in case series but does not define the same survival time for everyone. Treatment-sensitive tumours, including some haematological neoplasms, may follow a very different course from refractory carcinomas with multiple metastases. Median survival estimates from drained-effusion series are influenced by selection of patients already symptomatic or unstable.

Local success is also measured by freedom from recurrence, symptom relief, days spent outside hospital and the ability to continue treatment. A procedure that successfully controls effusion does not in itself demonstrate improved cancer survival, although it may provide substantial clinical benefit. Haemodynamic, functional and oncological outcomes should therefore be reported separately and reassessed over time.

Complications of the disease and its treatments

The main disease-related complications are recurrent tamponade, constriction, low cardiac output and congestion with renal or hepatic impairment. Loculated collections may selectively compress one chamber and make the usual echocardiographic picture less apparent. Extension to the epicardium, myocardium or vascular structures may add arrhythmias, ischaemia and contractile dysfunction. Deterioration should therefore be interpreted as an overall cardiopericardial problem, especially when the amount of fluid seems insufficient to explain it.

Procedures may cause perforation, bleeding, arrhythmias, pneumothorax, injury to nearby structures and infection; the catheter may become obstructed or dislodged. After apparent improvement, renewed instability calls for distinguishing recurrence, mechanical complications and decompression syndrome. Pericardial windows and intrapericardial therapies may be followed by adhesions, residual collections or inflammatory problems, while more extensive surgery carries a greater burden. Image guidance, choice of access and postprocedural monitoring reduce but do not eliminate risks.

Preventing complications requires continuity between oncology and cardiology teams, with a clear plan for new symptoms, medication management and follow-up. Prompt action is decisive in compressive presentations; in stable phases, diagnostic precision helps avoid treatment directed at the wrong mechanism. The most useful care pathway brings together tumour control, haemodynamic safety and quality of life.

Bibliography
  1. Bussani R et al. Cardiac metastases. Journal of Clinical Pathology. 2007;60(1):27-34.
  2. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  3. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  4. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  5. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.
  6. Mori S et al. Pericardial effusion in oncological patients: current knowledge and principles of management. Cardio-Oncology. 2024;10:8.
  7. Takeda K et al. Higher sensitivity of pericardial fluid cytology than biopsy in malignant effusions with potential explanation of false-negative cytology: A multi-institutional analysis. Cytopathology. 2025;36(1):31-40.
  8. Lestuzzi C. Neoplastic pericardial disease: Old and current strategies for diagnosis and management. World Journal of Cardiology. 2010;2(9):270-279.
  9. Yan BP-Y et al. Balloon pericardiotomy for malignant pericardial effusion: the PMAP trial. European Heart Journal. 2026;47(9):1118-1120.
  10. Prabhakar Y et al. Pericardial decompression syndrome: A comprehensive review. World Journal of Cardiology. 2019;11(12):282-291.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.